about
A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice.Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific programImmunodeficiency-associated lymphomas.Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentationNoninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.Robust enumeration of cell subsets from tissue expression profilesHigh PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas.Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma.Chromatin modifying gene mutations in follicular lymphoma.Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemiaTargetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphomaLoss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1Non-oncogene Addiction to SIRT3 Plays a Critical Role in LymphomagenesisLenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialNoncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity
P50
Q33576286-C7E40029-7432-4D21-8E75-77871DB1678AQ33632062-E1904603-E05C-4868-B9A7-FCA71A0C1B83Q33671971-D2065DF6-DA10-4985-9959-02724CEAB82CQ34582666-D48760EE-DC69-41BC-AE1D-2CA54564ED8AQ34775840-6EBCE275-214F-4E45-993F-2BE2AFF4F7F1Q35063947-632BC671-6BD2-4324-9197-6F9A24D38F3FQ35189915-5295D017-AE13-4872-87D1-5BB1B2826EDEQ35723986-E0864B89-709C-4943-8940-8920C0FAF35AQ36539395-E14D6E9A-D7F3-4981-8CF4-5801EF8CB69CQ36628291-E59D32E0-0FB7-4B92-BA00-865388A29393Q38546592-42D40A50-0490-414F-B44C-AE892BCF6744Q42503470-827CB47E-7104-4A55-9956-5FB754F93411Q47678497-48F980CF-EED7-403C-854A-96DD5B7B3059Q47828228-C88F1789-7353-409C-B042-44F5BC0AC4C6Q62057736-163094A3-C170-49E5-9EA5-A36B69241DEEQ69575922-5A417F0A-F012-41DC-A135-D17F517E6A99Q88475996-AA2D1A57-B335-4561-86A4-95C2E5DCB87EQ91521807-B8F47D3E-740D-41B2-8BE8-52ACAD8732A3Q92658293-CD480B30-314B-40ED-8CB2-1DCBFA638F9EQ92668411-6C4DA219-CD9D-4564-8B55-C7A539C221E4Q92884419-0F66BDB1-E228-43C0-8597-3C6725B64D75
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-6309-9472
@en
name
Michael Green
@ast
Michael Green
@en
Michael Green
@es
Michael Green
@nl
Michael Green
@sl
type
label
Michael Green
@ast
Michael Green
@en
Michael Green
@es
Michael Green
@nl
Michael Green
@sl
prefLabel
Michael Green
@ast
Michael Green
@en
Michael Green
@es
Michael Green
@nl
Michael Green
@sl
P108
P106
P108
P31
P496
0000-0001-6309-9472